Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
Clinical trial NCT05467670 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05467670
- Sponsor
- Alexander B Olawaiye, MD
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-30
- Primary completion
- 2026-04-13
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.